2021
How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCareJoining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra
Montanari F, Orjuela-Grimm M. Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra. Current Hematologic Malignancy Reports 2021, 16: 52-60. PMID: 33544319, PMCID: PMC8117403, DOI: 10.1007/s11899-021-00606-8.Peer-Reviewed Original ResearchConceptsAdult age spectrumCombination of immunochemotherapyRecent FindingsClinical trialsRisk-stratified strategiesTreatment-related toxicityLarge prospective studiesFuture therapeutic approachesNovel therapeutic strategiesNovel target therapiesLymphoproliferative disordersPediatric populationProspective studyRetrospective studyClinical algorithmTreatment paradigmTreatment strategiesTherapeutic approachesTherapeutic strategiesCellular therapyHeterogeneous groupPTLDTherapyDiseaseImmunochemotherapy
2006
Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease
Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M, Linfomi I. Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease. British Journal Of Haematology 2006, 136: 301-304. PMID: 17233821, DOI: 10.1111/j.1365-2141.2006.06437.x.Peer-Reviewed Original ResearchConceptsFollicular Lymphoma International Prognostic IndexOverall survivalClinical featuresPrimary nodal marginal zone B-cell lymphomaHepatitis C virus serologyMarginal zone B-cell lymphomaNodal marginal zone B-cell lymphomaC virus serologyStage IV diseaseWorse overall survivalInternational Prognostic IndexB-cell lymphomaWorse OSPrognostic indexVirus serologyPrognostic assessmentRare diseaseMultivariate analysisLactate dehydrogenaseDiseasePatientsPrognosisLymphomaSerology